Doxifluridine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Doxifluridine
- Accession Number
- DB12947
- Description
Doxifluridine has been investigated for the treatment of Stomach Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Doxifluridine (DB12947)
- Weight
- Average: 246.1924
Monoisotopic: 246.065199677 - Chemical Formula
- C9H11FN2O5
- Synonyms
- 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
- 5-fluoro-5'-deoxyuridine
- 5'-deoxy-5-fluorouridine
- 5'-DFUR
- Doxifluridina
- Doxifluridine
- Doxifluridinum
- External IDs
- RO 21-9738
- RO 219738
- RO-219738
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Doxifluridine. Acenocoumarol The risk or severity of bleeding can be increased when Doxifluridine is combined with Acenocoumarol. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Doxifluridine. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Doxifluridine. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxifluridine. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Doxifluridine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxifluridine. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Doxifluridine. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Doxifluridine. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Doxifluridine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- International/Other Brands
- Flutron / Furtulon
Categories
- Drug Categories
- Antimetabolites
- Antineoplastic Agents
- Appetite Stimulants
- Carbohydrates
- Central Nervous System Agents
- Central Nervous System Stimulants
- Deoxyribonucleosides
- Deoxyuridine
- Fluoropyrimidines
- Fluorouracil and prodrugs
- Glycosides
- Immunologic Factors
- Immunosuppressive Agents
- Isomerism
- Noxae
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleosides
- Pyrimidine Nucleosides
- Pyrimidines
- Ribonucleosides
- Toxic Actions
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- 5'-deoxyribonucleosides
- Sub Class
- Not Available
- Direct Parent
- 5'-deoxyribonucleosides
- Alternative Parents
- Glycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols show 9 more
- Substituents
- 1,2-diol / 5'-deoxyribonucleoside / Alcohol / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Glycosyl compound / Halopyrimidine / Heteroaromatic compound show 20 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- organofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521)
Chemical Identifiers
- UNII
- V1JK16Y2JP
- CAS number
- 3094-09-5
- InChI Key
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N
- InChI
- InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
- IUPAC Name
- 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(=O)NC1=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0060406
- KEGG Drug
- D01309
- KEGG Compound
- C12739
- PubChem Compound
- 18343
- PubChem Substance
- 347829090
- ChemSpider
- 17322
- BindingDB
- 50132295
- ChEBI
- 31521
- ChEMBL
- CHEMBL1130
- ZINC
- ZINC000001319177
- Wikipedia
- Doxifluridine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Supportive Care Malignant Neoplasm of Stomach 1 3 Completed Treatment Malignant Neoplasm of Stomach 2 1 Completed Treatment Liver Cancer / Metastatic Cancers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 37.7 mg/mL ALOGPS logP -0.77 ALOGPS logP -1.2 ChemAxon logS -0.81 ALOGPS pKa (Strongest Acidic) 8.07 ChemAxon pKa (Strongest Basic) -3.6 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 99.1 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 51.22 m3·mol-1 ChemAxon Polarizability 20.99 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 21, 2016 01:32 / Updated on February 21, 2021 18:54